Glenmark Pharma launches broad-spectrum antibiotic for bacterial pathogens

Glenmark Pharmaceuticals Inc., USA, has announced the commercial availability of Vancomycin Hydrochloride for Injection USP in three single-dose vial strengths: 750 mg/vial, 1.25 g/vial, and 1.5 g/vial. The drug is bioequivalent and therapeutically equivalent to Mylan Laboratories Limited's reference listed drug (NDA 209481) and is a valuable alternative for the treatment of serious bacterial infections.

Vancomycin Hydrochloride is a broad-spectrum antibiotic that is also utilized as a first-line agent for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) and other serious bacterial pathogens. With this product's launch, Glenmark is further establishing its presence in the institutional pharmaceutical market by addressing increasing demand within the U.S. healthcare environment for critical antibiotics. Based on IQVIA™ sales data through the 12 months ending January 2025, the Vancomycin Hydrochloride for Injection market has recorded around $39.3 million in annual sales, highlighting the immense demand for this life-saving drug.

Marc Kikuchi, Glenmark Pharmaceuticals' President & Business Head of North America, was bullish on the launch, saying, "We are looking forward to marketing Vancomycin Hydrochloride for Injection USP in 750 mg, 1.25 g, and 1.5 g vial presentations, adding another high-quality product to our institutional portfolio."

This action is another step in the continued efforts of Glenmark Pharmaceuticals to expand its injectable product line, demonstrating the company's dedication to providing inexpensive, effective treatments to patients in the United States.